SUNSHINE BIOPHARMA COMPLETES THE ACQUISITION OF ATLAS

SUNSHINE BIOPHARMA COMPLETES THE ACQUISITION OF ATLAS

Quebec, Canada -- (ACCESSWIRE) On January 1, 2018, Sunshine

Biopharma Inc. (OTCBB: SBFM ), a pharmaceutical

company focused on the research, development and commercialization

of drugs for the treatment of various forms of cancer, completed

the acquisition of Atlas Pharma Inc., a Montreal-based analytical

chemistry company fully accredited by Health Canada and registered

with the FDA. Atlas Pharma is a certified company dedicated to

chemical analysis of pharmaceutical and other industrial samples.

The acquisition price of $0.85 million Canadian (approximately

$0.68 million US) was paid in cash, long-term debt and Common Stock

Pharma has 9 full-time employees and generated revenues of

approximately $500,000 Canadian (approximately $400,000 US) in

2017. Housed in a 5,250 square foot facility, Atlas Pharma

operations are authorized by a Drug Establishment License (DEL)

issued by Health Canada and are fully compliant with the

requirements of Good Manufacturing Practices (GMP). More

information about Atlas Pharma is available at www.atlaspharmainc.ca.

intends to expand Atlas' business operations by purchasing

additional equipment and hiring more technical and sales

About Sunshine Biopharma

Biopharma is pharmaceutical company committed to becoming more

fully integrated by offering pharmaceutical services and generic

drugs in addition to its original proprietary drug development

program. The Company is currently undertaking a brokered private

placement of up to $10 million in Canada and intends to use the net

proceeds from this offering for implementation of the

Company's business plan including the clinical development of

Adva-27a, the Company's flagship anticancer compound. Tests

conducted on Adva-27a have demonstrated the drug's

effectiveness at destroying multidrug resistant cancer cells

including Pancreatic Cancer cells, Breast Cancer cells, Uterine

Sarcoma cells and Small-Cell Lung Cancer cells. Clinical trials for

Pancreatic Cancer indication are planned to be conducted at McGill

University's Jewish General Hospital in Montreal,

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not

strictly historical, including statements as to revenue

projections, business strategy, outlook, objectives, future

milestones, plans, intentions, goals, future financial conditions,

future collaboration agreements, the success of the Company's

development, events conditioned on stockholder or other approval,

or otherwise as to future events, such statements are

forward-looking, and are made pursuant to the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995.

The forward-looking statements contained in this release are

subject to certain risks and uncertainties that could cause actual

results to differ materially from the statements made.

For Additional Information Contact: